ÂÜÀòÂÒÂ×

Paloma Cejas, PhD is the Co-Founder of CURE51, a company that focuses on multiomics in long survivals of lethal Cancers for target identification. Prior to this, Paloma served as the Head of Innovation at Dana-Farber Cancer Institute and as the Director of Early Target Biology at Exo Therapeutics. With a background in translational research, Paloma has also held positions at Instituto de Investigación Hospital Universitario La Paz and Dana-Farber Cancer Institute. Additionally, Paloma has served as an Instructor in Medicine at Harvard Medical School.